<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613401</url>
  </required_header>
  <id_info>
    <org_study_id>20-9312-BO</org_study_id>
    <nct_id>NCT04613401</nct_id>
  </id_info>
  <brief_title>Influence of Telemonitoring on the Management of LVAD-patients</brief_title>
  <official_title>Association of Telemonitoring With Hospitalization Rates and Quality of Life in Patients With End-stage Heart Failure and Implanted Left Ventricular Cardiac Assist Devices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Essen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to investigate whether telemedical monitoring in patients with&#xD;
      terminal heart failure and an implanted left ventricular assist device (LVAD) has an&#xD;
      influence on LVAD-associated complications, hospitalization rates and quality of life. This&#xD;
      is a prospective observational study. Patients with terminal heart failure and an implanted&#xD;
      LVAD, where the indication for telemonitoring has already been stated by the attending&#xD;
      physician are included in the study. Written informed consent is obtained from all patients.&#xD;
      The telemedical monitoring is carried out by the West German Center for Applied Telemedicine&#xD;
      (WZAT) and includes a standardized telephone interview every 3 days. In addition, all&#xD;
      patients are equipped with an INR measuring device, a body scale and a clinical thermometer&#xD;
      by WZAT. The data is documented in an electronic case file (medPower®). In the event of&#xD;
      abnormalities, the West German Heart and Vascular Center (WHGZ) is contacted, and all&#xD;
      necessary measures are initiated.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of days spent in the hospital due to VAD-associated complications</measure>
    <time_frame>6 months</time_frame>
    <description>VAD-associated complications are defined as&#xD;
bleeding with the need for a transfusion&#xD;
infection with the need for an antibiotic therapy&#xD;
thrombosis with the need for a lysis therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Quality of life will be assessed with the &quot;Kansas City Cardiomyopathy Questionnaire (KCCQ) &quot;&#xD;
-&gt; The raw values of the domains are transformed to a scale from 0 to 100, where high values indicate good condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in depression from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>- Depression will be assessed with the &quot;Patient Health Questionnaire eight-item depression scale&quot; (PHQ-8)&#xD;
-&gt; The raw values of the domains are transformed to a scale from 0 to 24, where high values indicate a depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of VAD-associated complications</measure>
    <time_frame>6 months</time_frame>
    <description>VAD-associated complications are defined as&#xD;
bleeding with the need for a transfusion&#xD;
infection with the need for an antibiotic therapy&#xD;
thrombosis with the need for a lysis therapy</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ventricular Assist Device</condition>
  <condition>Telemedicine</condition>
  <arm_group>
    <arm_group_label>VAD-patients with Telemonitoring</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaire (observational study)</intervention_name>
    <description>questionnaire about hospitalisation rates, complications (bleeding, infection, thrombosis), quality of life (Kansas-Score), depression (PHQ8)</description>
    <arm_group_label>VAD-patients with Telemonitoring</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with terminal heart failure and LVAD-therapy who are monitored by telemedicine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt; 18 years&#xD;
&#xD;
          -  Indication for telemedicine&#xD;
&#xD;
          -  Permanently implanted left ventricular assist device (VAD)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no possibility of telephone contact&#xD;
&#xD;
          -  patient does not speak german&#xD;
&#xD;
          -  incompliance&#xD;
&#xD;
          -  rejection or inability to give consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julia Hoffmann</last_name>
    <phone>+49 201 723 85587</phone>
    <email>julia.hoffmann@uk-essen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University Hospital Essen</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Hoffmann</last_name>
      <phone>+49 201 723 85587</phone>
      <email>julia.hoffmann@uk-essen.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Bundesärztekammer (BÄK) KBK, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz - Langfassung, 2. Auflage. Version 3. 2017.</citation>
  </reference>
  <reference>
    <citation>Bundesauswertung zum Erfassungsjahr 2018: Herzunterstützungssysteme/Kunstherzen; Qualitätsindikatoren und Kennzahlen. IQTIG - Institut für Qualitätssicherung und Transparenz im Gesundheitswesen; 2019 .</citation>
  </reference>
  <results_reference>
    <citation>Reiss N, Schmidt T, Boeckelmann M, Schulte-Eistrup S, Hoffmann JD, Feldmann C, Schmitto JD. Telemonitoring of left-ventricular assist device patients-current status and future challenges. J Thorac Dis. 2018 Jun;10(Suppl 15):S1794-S1801. doi: 10.21037/jtd.2018.01.158. Review.</citation>
    <PMID>30034855</PMID>
  </results_reference>
  <results_reference>
    <citation>Kimura M, Nawata K, Kinoshita O, Yamauchi H, Hoshino Y, Hatano M, Amiya E, Kashiwa K, Endo M, Kagami Y, Nemoto M, Ono M. Readmissions after continuous flow left ventricular assist device implantation. J Artif Organs. 2017 Dec;20(4):311-317. doi: 10.1007/s10047-017-0975-4. Epub 2017 Jul 27.</citation>
    <PMID>28752193</PMID>
  </results_reference>
  <results_reference>
    <citation>Smedira NG, Hoercher KJ, Lima B, Mountis MM, Starling RC, Thuita L, Schmuhl DM, Blackstone EH. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. JACC Heart Fail. 2013 Feb;1(1):31-9. doi: 10.1016/j.jchf.2012.11.001. Epub 2013 Feb 4.</citation>
    <PMID>24621797</PMID>
  </results_reference>
  <results_reference>
    <citation>Reiss N, Wegner KK, Hoffmann JD, Schulte Eistrup S, Boeken U, Morshuis M, Schmidt T. Requirements for a Telemedicine Center to Monitor LVAD Patients. Stud Health Technol Inform. 2019;260:146-153.</citation>
    <PMID>31118331</PMID>
  </results_reference>
  <results_reference>
    <citation>Böhm M, Drexler H, Oswald H, Rybak K, Bosch R, Butter C, Klein G, Gerritse B, Monteiro J, Israel C, Bimmel D, Käab S, Huegl B, Brachmann J; OptiLink HF Study Investigators. Fluid status telemedicine alerts for heart failure: a randomized controlled trial. Eur Heart J. 2016 Nov 1;37(41):3154-3163. Epub 2016 Mar 16.</citation>
    <PMID>26984864</PMID>
  </results_reference>
  <results_reference>
    <citation>Hindricks G, Taborsky M, Glikson M, Heinrich U, Schumacher B, Katz A, Brachmann J, Lewalter T, Goette A, Block M, Kautzner J, Sack S, Husser D, Piorkowski C, Søgaard P; IN-TIME study group*. Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial. Lancet. 2014 Aug 16;384(9943):583-590. doi: 10.1016/S0140-6736(14)61176-4.</citation>
    <PMID>25131977</PMID>
  </results_reference>
  <results_reference>
    <citation>Koehler F, Koehler K, Deckwart O, Prescher S, Wegscheider K, Kirwan BA, Winkler S, Vettorazzi E, Bruch L, Oeff M, Zugck C, Doerr G, Naegele H, Störk S, Butter C, Sechtem U, Angermann C, Gola G, Prondzinsky R, Edelmann F, Spethmann S, Schellong SM, Schulze PC, Bauersachs J, Wellge B, Schoebel C, Tajsic M, Dreger H, Anker SD, Stangl K. Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2): a randomised, controlled, parallel-group, unmasked trial. Lancet. 2018 Sep 22;392(10152):1047-1057. doi: 10.1016/S0140-6736(18)31880-4. Epub 2018 Aug 25.</citation>
    <PMID>30153985</PMID>
  </results_reference>
  <results_reference>
    <citation>Berg T, Tewarie L, Moza A, Zayat R, Autschbach R, Stoppe C, Goetzenich A, Benstoem C. [Requirements for outpatient care after implantation of a ventricular assist device : Views of patients and their relatives]. Herz. 2019 May;44(3):257-264. doi: 10.1007/s00059-017-4636-4. Epub 2017 Oct 27. German.</citation>
    <PMID>29079934</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

